Lipoprotein(a) and Cardiovascular Disease: Evidence, Recommendations and Emerging Therapies
Abstract
Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL) like particle which has atherogenic, proinflammatory and prothrombotic properties. Elevated in approximately 1 in 5 persons, increased levels of Lp(a) have been shown by epidemiological, genome wide association studies and Mendelian randomisation studies to be a causal factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is primary genetically determined and is more atherogenic than LDL. Current recommendations from Europe, Canada, India and the United States recommend testing at least once in all adults. Persons found to have elevated levels (eg, > 50 mg/dL or > 125 nmol/L) are recommended for more intensive risk factor management, including further LDL-C lowering. With lipoprotein apheresis the only currently approved therapy for lowering Lp(a), several newer antisense oligonucleotide (ASO) and small interfering RNA (siRNA) therapies are in development and may soon provide additional therapeutic options for persons with elevated Lp(a). Several cardiovascular outcomes trials are underway involving these new therapies with the first to read out in 2026. Lp(a) is a key risk factor that warrants greater attention for testing, with further efforts to reduce ASCVD in those found to have elevated levels, especially in higher risk persons.
References
Jones JE, Tang KS, Barseghian A, Wong ND. Evolution of more aggressive LDL- cholesterol targets and therapies for cardiovascular disease prevention. J Clin Med. 2023 Nov 30;12(23):7432. doi: 10.3390/jcm12237432.
Wong ND, Shapiro MD. Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials. Front Cardiovasc Med. 2019 Mar 6;6:14. doi: 10.3389/fcvm.2019.00014.
Wong ND, Zhao Y, Quek RGW, Blumenthal RS, Budoff MJ, Cushman M, ET AL. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol 2017. 120(7):1220-2. doi: 10.1016/j.jacl.2017.06.015.
Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042.
Björnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein b-based genetic analysis. J Am Coll Cardiol. 2024;83(3):385-95. doi: 10.1016/j.jacc.2023.10.039.
Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, et al; INTERHEART Investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019 Mar 19;139(12):1472-82. doi: 10.1161/CIRCULATIONAHA.118.034311.
Emerging Risk Factors Collaboration; Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-23. doi: 10.1001/jama.2009.1063.
Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146-56. doi: 10.1016/j.jacc.2012.12.023.
Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28. doi: 10.1056/NEJMoa0902604.
CARDIoGRAMplusC4D Consortium; Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25-33. doi: 10.1038/ng.2480.
Thomas PE, Vedel-Krogh S, Nielsen SF, Nordestgaard BG, Kamstrup PR. Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events. J Am Coll Cardiol. 2023 Dec 12;82(24):2265-76. doi: 10.1016/j.jacc.2023.10.009.
Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S. Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2018 Dec 1;3(12):1212-7. doi: 10.1001/jamacardio.2018.3798.
Wong ND, Fan W, Hu X, Ballantyne C, Hoodgeveen RC, Tsai MY, et al. Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. J Am Coll Cardiol. 2024 Apr 23;83(16):1511-25. doi: 10.1016/j.jacc.2024.02.031.
Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, et al. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(9):873-86. doi: 10.1016/j.jacc.2023.12.031.
Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, et al. Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation. 2025 Jan 28;151(4):312-21. doi: 10.1161/CIRCULATIONAHA.124.069556.
Wong ND, Zhao Y, Xiang P, Coll B, López JAG. Five-year residual atherosclerotic cardiovascular disease risk prediction model for statin treated patients with known cardiovascular disease. Am J Cardiol. 2020 Dec 15;137:7-11. doi: 10.1016/j.amjcard.2020.09.043.
SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-54. doi: 10.1093/eurheartj/ehab309.
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73. doi: 10.1161/01.cir.0000437741.48606.98.
Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014 Sep 2;64(9):851-60. doi: 10.1016/j.jacc.2014.03.061.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-46. doi: 10.1093/eurheartj/ehac361.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147.
Fan W, Wu C, Wong ND. Lipoprotein(a) atherosclerotic cardiovascular disease risk score development and prediction in primary prevention from real-world data. Circ Genom Precis Med. 2025 Jan 24:e004631. doi: 10.1161/CIRCGEN.124.004631
Hu X, Cristino J, Gautam R, Mehta R, Amari D, Heo JH, et al. Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study. Am J Prev Cardiol. 2023 Feb 23;14:100476. doi: 10.1016/j.ajpc.2023.100476.
Bhatia HS, Hurst S, Desai P, Zhu W, Yeang C. Lipoprotein(a) testing trends in a large academic health system in the United States. J Am Heart Assoc. 2023;12(18):e031255. doi: 10.1161/JAHA.123.031255.
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021 Aug;37(8):1129-50. doi: 10.1016/j.cjca.2021.03.016.
Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, et al. Lipoprotein(a) and ASCVD risk. J Assoc Physicians India. 2020 Nov;68(11[Special]):42-6. PMID: 33350614.
Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. doi: 10.1016/j.jacl.2024.03.001.
Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024 Apr 3;18:100651. doi: 10.1016/j.ajpc.2024.100651.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al; AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020 Jan 16;382(3):244-55. doi: 10.1056/NEJMoa1905239.
ClinicalTrials.gov. [Internet]. Assessing the impact of lipoprotein (a) lowering with pelacarsen (tqj230) on major cardiovascular events in patients with CVD (Lp(a)HORIZON). [Cited: 26-Feb-25]. Available at: https://clinicaltrials.gov/study/NCT04023552.
O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al; OCEAN(a)-DOSE Trial Investigators. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022 Nov 17;387(20):1855-64. doi: 10.1056/NEJMoa2211023.
ClinicalTrials.gov. [Internet]. OLpasiran trials of cardiovascular events and lipoprotein(a) reduction (OCEAN(a)) - Outcomes Trial. [Cited: 25-Feb-25]. Available at: https://clinicaltrials.gov/study/NCT05581303.
Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA. 2024 Dec 17;332(23):1992-2002. doi: 10.1001/jama.2024.21957.
Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2025 Jan 21;333(3):222-31. doi: 10.1001/jama.2024.24017.
Tsimikas S, Yang X, Hsieh A, Ditmarsch M, Davidson M, Kastelein J. Obicetrapib demonstrates significant deductions of lp(a) on top of high-intensity statins. Am Heart J 2024;278 (suppl):3. doi: 10.1016/j.ahj.2024.09.013.
Verve Therapeutics [Internet]. Genetic targets. [Cited: 26-Feb-25]. Available at: https://www.vervetx.com/our-science/genetic-targets.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).